Lot certificates published
Plain, secure packaging

same family

Tirzepatide vs Retatrutide

Tirzepatide and retatrutide are distinct members of the Library’s multi-receptor incretin analog class, with separate development codes and molecular identities.

Published: 2026-10-03Library record comparison: 2026-10-03

01

Identity side by side

Recorded molecular identities of Tirzepatide and Retatrutide
Recorded fieldTirzepatideRetatrutide
Canonical nameTirzepatideRetatrutide
Aliasesnot recordednot recorded
Development codesLY3298176LY3437943
CAS2023788-19-22381089-83-2
UNIIOYN3CCI6QENOP2Y096GV
PubChem CID166567236not recorded
Molecular formulaC225H348N48O68not recorded
Molecular weight (Da)4813not recorded
Sequence length (residues)39not recorded
Terminal modificationsFree N-terminus; C-terminal amide at Ser39Free N-terminus; C-terminal amidation
Structural modificationsFatty-acid moiety linked to the peptide backbonenot recorded

Tirzepatide: nomenclature notes

The discovery record identifies the molecule under the development code LY3298176. GSRS UNII OYN3CCI6QE identifies the specified tirzepatide sequence and modifications and lists CAS 2023788-19-2, although its retrieved codes do not include PubChem CID 166567236.

Retatrutide: nomenclature notes

Retatrutide is the adopted name used for the development compound LY3437943 in the verified bibliography. It is a proposed International Nonproprietary Name, published in WHO Proposed INN List 128 (WHO Drug Information, Vol. 36, No. 4, 2022). PubChem CID 171934787 encodes a fully stereospecified free-peptide candidate despite its sodium-salt title; its position-13 configuration matches the GSRS systematic definition, but this record’s independent configuration conflict remains unresolved.

02

Recorded modification details

An aligned one-letter sequence is not recorded for this pair. The stored modification and sequence notes are shown below.

Tirzepatide

Terminal modifications
Free N-terminus; C-terminal amide at Ser39
Structural modifications
Fatty-acid moiety linked to the peptide backbone
Stored three-letter notation
Tyr · Aib · Glu · Gly · Thr · Phe · Thr · Ser · Asp · Tyr · Ser · Ile · Aib · Leu · Asp · Lys · Ile · Ala · Gln · Lys · Ala · Phe · Val · Gln · Trp · Leu · Ile · Ala · Gly · Gly · Pro · Ser · Ser · Gly · Ala · Pro · Pro · Pro · Ser
Sequence notes
Thirty-nine residues numbered from the N-terminus; the C-terminal amide on Ser39 is recorded as a terminal group, not as a residue. NO one-letter string is published here: positions 2 and 13 are both Aib, 2-aminoisobutyric acid, and no standard letter names that residue. Residue 1 is Tyr, the GIP N-terminus rather than GLP-1's His. There are two lysines, at 16 and 20, and the acylation site is Lys20. The backbone is not the whole molecule: that Lys20 side chain is acylated through two AEEA spacers and a gamma-L-glutamyl unit to a C20 dicarboxylic fatty acid. Summing the thirty-nine residues with Aib at 2 and 13, removing thirty-eight waters, applying the Ser39 amide, then adding two AEEA units, one glutamyl unit and eicosanedioic acid less the four waters of the four amide bonds, gives C225H348N48O68, reproducing the recorded formula exactly; the derived average mass is 4813.53 Da against a recorded 4813, which is a truncation of that value rather than a rounding of it. Residues 29 to 39 are Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; that tail is shared with other 39-residue incretin peptides and is not by itself evidence of ancestry, which the structural notes take up. That arithmetic is the identity check this record rests on; the automated sequence verifier cannot reach it, because Aib and the acyl side chain are outside its derivation model.

Retatrutide

Terminal modifications
Free N-terminus; C-terminal amidation
Structural modifications
not recorded
Sequence notes
Described in words and attributed, not recorded as a verified structure. WHO Proposed INN List 128 describes retatrutide as a 39-residue peptide with a C-terminal amide. In three-letter symbols, the residue order it gives is Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, where Aib is 2-aminoisobutyric acid (positions 2 and 20) and αMeLeu is 2-methylleucine (position 13), which the WHO entry specifies as the L form. The lysine at position 17 carries a side chain on its ε-amino group, built outward from one 8-amino-3,6-dioxaoctanoyl unit, one γ-glutamyl unit and eicosanedioic acid attached as a mono-amide. No one-letter string is recorded, because a letter string cannot show the three non-standard residues or the side chain. The same residue order and side-chain construction appear in the sponsor patent WO2019125938A1 and in an independently authored synthesis patent, CN117024528B. The drawing of the position-13 residue in CN117024528B shows the opposite configuration to the one WHO specifies; whether that is a different stereoisomer or a drawing error is not established here.

03

Recorded mechanisms

These lists show the links recorded in each monograph. An unlisted link does not establish its absence from the molecule’s biology.

Recorded only for Tirzepatide

not recorded

Recorded only for Retatrutide

04

Recorded compound classes

Shared recorded links

Recorded only for Tirzepatide

not recorded

Recorded only for Retatrutide

not recorded

05

References for the relationship

  1. Reference 1

    LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

    Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A

    Molecular metabolism · 2018-10-03 · Journal Article

    current
  2. Reference 2

    LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

    Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z

    Cell metabolism · 2022-08-18 · Journal Article

    current

Study models of these references

What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.

ReferenceStudy models
Coskun T et al. 2018Study models reported: in vitro; animal (mouse); human participants (interventional) · from the abstract
Coskun T et al. 2022Study models reported: in vitro; animal (mouse); human participants (interventional) · from the abstract

06

Read the full monographs